Loading clinical trials...
Loading clinical trials...
Identification of Risk Factors and Development of an Interpretable Machine Learning Model for Predicting Insulin Resistance in Patients With Psoriasis
Psoriasis is a long-term inflammatory skin disease that can affect overall health. People with psoriasis have a higher risk of developing insulin resistance, a condition in which the body does not respond properly to insulin. Insulin resistance can increase the risk of diabetes, heart disease, and other serious health problems. Because insulin resistance often develops without clear symptoms, many patients are not diagnosed early. The purpose of this study is to identify which patients with psoriasis are more likely to develop insulin resistance and to create a tool that can help doctors estimate this risk for individual patients. The study will use existing medical records from two medical centers. Researchers will analyze information such as age, body weight, psoriasis severity, blood test results, other medical conditions, and medication history. Machine learning methods will be used to analyze these data and build a prediction model. The model will be designed to be easy to understand, so doctors can see which factors contribute most to insulin resistance risk. This study does not involve any new treatments or procedures. All patient information will be anonymized to protect privacy. The results may help doctors identify high-risk patients earlier and support timely monitoring and preventive care.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Chinese PLA General Hosptial
Beijing, None Selected, China
Start Date
September 1, 2025
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2026
Last Updated
January 7, 2026
1,265
ESTIMATED participants
Lead Sponsor
Chinese PLA General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07449234